Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMX 0114

Next Previous
X
Search
Drug Profile

AMX 0114

Alternative Names: AMX-0114

Latest Information Update: 22 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amylyx Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Calpain expression inhibitors; Gene silencing
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Neurodegenerative disorders

Most Recent Events

  • 09 May 2024 Amylyx Pharmaceuticals announces intention to submit an investigational new drug (IND) application to the US FDA for the clinical study of AMX 0114 in amyotrophic lateral sclerosis in the second half of 2024
  • 04 Apr 2024 Amylyx Pharmaceuticals plans a clinical trial for Amyotrophic lateral sclerosis in the second half of 2024
  • 11 Mar 2024 Interim pharmacodynamics data from a preclinical studies in Amyotrophic lateral sclerosis released by Amylyx Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top